Related references
Note: Only part of the references are listed.Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice
Rania Salah et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer
Mohamad Javad Mirzaei-Parsa et al.
BREAST CANCER (2020)
Evaluation of the Cardiac Protection Conferred by Proanthocyanidins in Grape Seeds against Development of Ehrlich Solid Tumors in Mice
Maha Abdulrahman Aldubayan
BIOMED RESEARCH INTERNATIONAL (2020)
Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes
Poliana Camila Marinello et al.
SCIENTIFIC REPORTS (2019)
The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo
Kevin Sean Murnane et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2019)
Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy
Qiu-Lan Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
Amira Saleh et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2019)
Antineoplastic Activity and Curative Role of Avenanthramides against the Growth of Ehrlich Solid Tumors in Mice
Maha A. Aldubayan et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Contribution of Angiogenesis to Inflammation and Cancer
Dolores Aguilar-Cazares et al.
FRONTIERS IN ONCOLOGY (2019)
Ginger extract adjuvant to doxorubicin in mammary carcinoma: study of some molecular mechanisms
Nahla E. El-Ashmawy et al.
EUROPEAN JOURNAL OF NUTRITION (2018)
Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model
Somayeh Ashrafi et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1
Hanaa S. E. Mousa et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome
Rita Haldar et al.
BRAIN BEHAVIOR AND IMMUNITY (2018)
Ki-67: more than a proliferation marker
Xiaoming Sun et al.
CHROMOSOMA (2018)
Toxicity of Doxorubicin (Dox) to different experimental organ systems
Arivalagan Pugazhendhi et al.
LIFE SCIENCES (2018)
Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy
Srishti Agarwal et al.
RSC ADVANCES (2018)
Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats
Abidemi J. Akindele et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer
Alexa Montoya et al.
ONCOTARGET (2017)
Peceosomes for oral delivery of glibenclamide: In vitro in situ correlation
Amal A. Sultan et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2017)
Maximizing the Therapeutic Efficacy of Imatinib Mesylate-Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design
Mohammed A. Kassem et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway
Nahla E. El-Ashmawy et al.
TUMOR BIOLOGY (2017)
The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice
Veronika Hanusova et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Synergistic efficacy of γ-radiation together with gallium trichloride and/or doxorubicin against Ehrlich carcinoma in female mice
Eman Kandil et al.
TUMOR BIOLOGY (2016)
Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin
Maria A. Carvalho Rodrigues et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2016)
Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators
Keyvan Amirshahrokhi et al.
CYTOKINE (2016)
Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicin-treated mice
Almokhtar A. Adwas et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2016)
Colloidal carriers for extended absorption window of furosemide
Amal A. Sultan et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Solid Ehrlich carcinoma reproduces functional and biological characteristics of cancer cachexia
Fernando Tadeu Trevisan Frajacomo et al.
LIFE SCIENCES (2016)
Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model
Ying Chen et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Effects of VEGF/VEGFR/K-ras signaling pathways on miRNA21 levels in hepatocellular carcinoma tissues in rats
J. Z. Gao et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Effect of metformin and adriamycin on transplantable tumor model
Ahmed M. Kabel et al.
TISSUE & CELL (2015)
Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin
Naglaa F. Khedr et al.
TUMOR BIOLOGY (2015)
Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway
Qian Ding et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy
Yung-Lung Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Nano-niosomes as nanoscale drug delivery systems: An illustrated review
Saeid Moghassemi et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice
Amany A. Abdin et al.
PHARMACOLOGICAL REPORTS (2014)
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
E. Pasquier et al.
BRITISH JOURNAL OF CANCER (2013)
Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system
Azza A. Hasan et al.
DRUG DELIVERY (2013)
Use of β-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study
Gitte Vrelits Sorensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Preparation, characterization and anticancer therapeutic efficacy of cisplatin-loaded niosomes
Hong Yang et al.
JOURNAL OF MICROENCAPSULATION (2013)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice
Samiha M. Abd El-Dayem et al.
TOXICOLOGY AND INDUSTRIAL HEALTH (2013)
Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits
Sohail Akhter et al.
EUROPEAN JOURNAL OF NANOMEDICINE (2013)
Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Steven W. Cole et al.
CLINICAL CANCER RESEARCH (2012)
PLGA-based nanoparticles: An overview of biomedical applications
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Beta-adrenergic blocking drugs in breast cancer: a perspective review
Thomas I. Barron et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
The beta 2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
Ming Shi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines
Kelley S. Madden et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types
Dimitrios Iliopoulos et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Goncalo C. Pereira et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Mechanisms and management of doxorubicin cardiotoxicity
Y. Shi et al.
HERZ (2011)
Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism
Soon Young Park et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
Amal Melhem-Bertrandt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast
Else Maae et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan et al.
CANCER RESEARCH (2010)
Biodegradable polymeric nanoparticles based drug delivery systems
Avnesh Kumari et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2010)
Carvedilol in glioma treatment alone and with imatinib in vitro
Mine Erguven et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels
Chris M. van der Loos et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2010)
Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival
Desmond G. Powe et al.
ONCOTARGET (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer
Michael H. Antoni et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein
Fa Yun Zhang et al.
PHARMACEUTICAL RESEARCH (2009)
Intracellular redox status and oxidative stress:: implications for cell proliferation, apoptosis, and carcinogenesis
Jose M. Mates et al.
ARCHIVES OF TOXICOLOGY (2008)
Angiogenesis in pre-malignant conditions
S. R. Menakuru et al.
BRITISH JOURNAL OF CANCER (2008)
Protection of multiple antioxiclants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy
Xu-Jun Qin et al.
JOURNAL OF APPLIED TOXICOLOGY (2008)
Propranolol for severe hemangiomas of infancy
Christine Leaute-Labreze et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway
A. E. Carie et al.
ONCOGENE (2007)
Influence of Agaricus blazei Murrill in solid Ehrlich tumor and popliteal lymph nodes in mice
D. Vercosa Junior et al.
ARQUIVO BRASILEIRO DE MEDICINA VETERINARIA E ZOOTECNIA (2007)
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Premal H. Thaker et al.
NATURE MEDICINE (2006)
Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance
K Takara et al.
ANTI-CANCER DRUGS (2004)
Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol
Y Mukai et al.
INTERNAL MEDICINE (2004)
The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
WM Awara et al.
PHARMACOLOGICAL RESEARCH (2004)
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center
MF Azzola et al.
CANCER (2003)
Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil
M Kakumoto et al.
CANCER SCIENCE (2003)
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance
E Devarajan et al.
ONCOGENE (2002)
The syndrome of cardiac cachexia
SD Anker et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2002)
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure
RA de Boer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2001)
Antioxidant action, of the antihypertensive drug, carvedilol, against lipid peroxidation
N Noguchi et al.
BIOCHEMICAL PHARMACOLOGY (2000)
beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells
TA Slotkin et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
